- Report
- November 2025
- 200 Pages
Global
From €7140EUR$7,950USD£6,099GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1123EUR$1,250USD£959GBP
- Report
- June 2025
- 150 Pages
Global
From €2424EUR$2,699USD£2,071GBP
- Report
- May 2024
- 129 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
Erosive Esophagitis (EE) is a type of Gastrointestinal (GI) disorder that is caused by the inflammation of the esophagus due to acid reflux. EE is a common disorder, and is often treated with medications such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs). These medications are used to reduce the amount of acid produced in the stomach, and to reduce the symptoms of EE.
The EE drug market is a subset of the larger GI drug market, and is composed of a variety of medications used to treat EE. These medications are available in both prescription and over-the-counter forms, and are used to reduce the symptoms of EE and to prevent further damage to the esophagus.
The EE drug market is highly competitive, with many companies offering a variety of medications to treat EE. Some of the major companies in the EE drug market include AstraZeneca, Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more